Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-445P is a **pseudogene** belonging to the U6 small nuclear RNA family, annotated in the human genome but believed to be transcriptionally inactive and not involved in any known biological processes or disease associations[2][6]. U6 snRNA itself is an essential part of the spliceosome involved in pre-mRNA splicing in eukaryotes, but **RNU6-445P** does not encode a functional snRNA product[5]. Pseudogenes like RNU6-445P arise from duplication or reverse transcription events that lead to nonfunctional copies of originally active genes[4][7]. There is no evidence suggesting that RNU6-445P contributes to spliceosome function, cellular processes, or disease mechanisms. This entry is best considered a **non-target, non-coding RNA pseudogene** with no known biological or therapeutic implications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 445, pseudogene (RNU6-445P).